The New Idea Award

Funding Agency:
Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society is proud to announce the fourth year of The New Idea Award, a grant program designed to identify novel research strategies with a potential for high impact on blood cancer. Specifically, this program supports the initial exploration of untested but potentially transformative ideas that challenge our knowledge of blood cancer or the manner in which we approach diagnosis or treatment. Competitive proposals will describe ideas that take the investigator’s research in a substantially new direction, and thus preliminary data is not required.

The goal of this program is to advance novel concepts that may eventually lead to significant improvements in the clinical outcomes of patients with blood cancer. Grants will support initial exploration of untested but potentially transformative ideas that may radically change the way we treat or understand blood cancer. In addition to applications from blood cancer researchers, we strongly encourage applications from those with expertise outside of blood cancer, with the goal of stimulating new research. In order to receive such an award, applicants must succinctly describe as one aim the innovative idea/approach and a method for testing it within the one year grant period.

Grants will be awarded in an amount of up to $75,000 for a one year period.


Deadline for Letter of Intent: July 31, 2017

Agency Website

Eligibility Requirements

Investigators in academic laboratories are eligible to apply. Researchers in any field are encouraged to apply, but the proposal must directly address blood cancer. Investigators must demonstrate that their research environment is equipped and suitable for the proposed study; this includes demonstrated access to patient materials, where applicable. Collaboration between multiple investigators to strengthen the proposed research will be considered favorably, but is not a requirement. Applicants need not be United States (U.S.) citizens nor be associated with a U.S.-based institution. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.



Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 31, 2017